Reed-Sternberg cells are distinctive, large, abnormal cells that are characteristically seen in Hodgkin lymphoma, a type of lymphatic cancer. These cells serve as a hallmark for diagnosing this disease and are central to understanding its pathology. Reed-Sternberg cells have a unique morphology, typically appearing as binucleated or multinucleated cells with prominent eosinophilic nucleoli, often described as having an owl’s eye appearance under the microscope. Their presence in lymph node biopsies is a critical diagnostic feature, distinguishing Hodgkin lymphoma from other lymphoid malignancies. Studying these cells provides insights into disease mechanisms, immune system interactions, and therapeutic strategies targeting the tumor microenvironment.
Characteristics of Reed-Sternberg Cells
Reed-Sternberg cells are large, abnormal B lymphocytes that have undergone malignant transformation. They are typically more than twice the size of normal lymphocytes and exhibit a bilobed nucleus with prominent nucleoli. The cytoplasm of these cells is abundant and eosinophilic, and their overall appearance is highly distinctive, which makes them easily recognizable in histological examinations. These cells are rare within affected tissue but exert significant influence on the surrounding microenvironment, recruiting inflammatory cells and altering immune responses.
Morphological Features
- Large, multinucleated or bilobed nucleus
- Prominent eosinophilic nucleoli giving the owl’s eye appearance
- Abundant cytoplasm
- Sparse in number relative to reactive background lymphocytes and inflammatory cells
The unique morphology of Reed-Sternberg cells is critical for pathologists when identifying Hodgkin lymphoma and differentiating it from other lymphomas or reactive lymphadenopathy.
Where Reed-Sternberg Cells Are Found
Reed-Sternberg cells are most characteristically seen in lymph nodes affected by classical Hodgkin lymphoma. These cells can also appear in extranodal sites, although lymph nodes are the primary locations where they are observed. The presence of Reed-Sternberg cells within a mixed inflammatory background, including eosinophils, plasma cells, and small lymphocytes, defines the histological architecture of Hodgkin lymphoma. Identifying these cells is essential for accurate diagnosis, staging, and treatment planning.
Primary Sites of Involvement
- Cervical lymph nodes – most commonly affected
- Axillary and mediastinal lymph nodes
- Extranodal sites – occasionally seen in spleen, liver, and bone marrow
- Reactive inflammatory milieu surrounding Reed-Sternberg cells
The typical distribution of these cells in lymph nodes and their histological context helps clinicians classify the subtype of Hodgkin lymphoma and determine prognosis.
Subtypes of Hodgkin Lymphoma
Reed-Sternberg cells are associated with classical Hodgkin lymphoma, which is divided into four main subtypes based on the histopathological pattern and cellular composition. These include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted Hodgkin lymphoma. Each subtype exhibits variations in the number of Reed-Sternberg cells, the type of inflammatory background, and clinical presentation. Reed-Sternberg cells may also display variant forms depending on the subtype, but their fundamental morphology remains a diagnostic cornerstone.
Classical Subtypes
- Nodular sclerosis – Reed-Sternberg cells with lacunar variants in fibrous nodules
- Mixed cellularity – abundant classic Reed-Sternberg cells in a mixed inflammatory background
- Lymphocyte-rich – fewer Reed-Sternberg cells surrounded by lymphocytes
- Lymphocyte-depleted – numerous Reed-Sternberg cells with scarce lymphocytes, often more aggressive
Recognizing the pattern of Reed-Sternberg cells in these subtypes is essential for accurate diagnosis and therapeutic planning.
Molecular and Immunophenotypic Features
Beyond their morphology, Reed-Sternberg cells have distinct immunophenotypic characteristics that aid in diagnosis. They typically express CD15 and CD30 surface markers while often lacking typical B-cell markers such as CD20. Molecular studies have shown that these cells originate from germinal center B cells but have lost much of their normal B-cell program. Understanding their molecular signature helps researchers study the pathogenesis of Hodgkin lymphoma and develop targeted therapies.
Key Immunophenotypic Markers
- CD15 – expressed on most classical Reed-Sternberg cells
- CD30 – strong surface expression
- CD20 – usually absent or weakly expressed
- PAX5 – weak expression, indicating B-cell origin
- EBV markers – occasionally positive, linking Epstein-Barr virus to pathogenesis
These molecular and immunohistochemical markers are used alongside morphology to confirm the presence of Reed-Sternberg cells and differentiate Hodgkin lymphoma from non-Hodgkin lymphomas.
Pathophysiological Role
Reed-Sternberg cells are not only diagnostic markers but also key players in the pathophysiology of Hodgkin lymphoma. They secrete cytokines and chemokines that attract inflammatory cells, which form a supportive microenvironment. This environment promotes tumor survival, immune evasion, and proliferation. Despite being relatively rare within the tumor mass, Reed-Sternberg cells orchestrate a network of interactions that drives disease progression and contributes to systemic symptoms such as fever, weight loss, and night sweats, known collectively as B symptoms.
Microenvironment Interactions
- Secretion of interleukins (IL-5, IL-13) and chemokines to recruit eosinophils and lymphocytes
- Formation of a reactive stroma that supports tumor growth
- Inhibition of effective anti-tumor immune responses
- Contribution to systemic symptoms via cytokine release
The ability of Reed-Sternberg cells to manipulate their microenvironment underscores their central role in Hodgkin lymphoma pathology.
Clinical Implications
Identifying Reed-Sternberg cells is crucial for the diagnosis, staging, and treatment of Hodgkin lymphoma. A biopsy showing these cells in an appropriate inflammatory background confirms the diagnosis. Their presence also guides treatment decisions, including chemotherapy, radiation therapy, and, in some cases, immunotherapy. Understanding the biology of Reed-Sternberg cells has led to the development of targeted therapies, such as monoclonal antibodies against CD30, which specifically attack these malignant cells while sparing normal lymphocytes.
Diagnostic and Therapeutic Importance
- Histopathology – key for confirming Hodgkin lymphoma
- Staging – influences treatment intensity and modality
- Prognosis – subtype and abundance of Reed-Sternberg cells correlate with outcomes
- Targeted therapy – CD30-directed treatments exploit the unique marker of these cells
Reed-Sternberg cells are characteristically seen in Hodgkin lymphoma and serve as the defining feature of this disease. Their unique morphology, immunophenotype, and role in shaping the tumor microenvironment make them central to both diagnosis and pathophysiology. These cells are typically large, multinucleated, with prominent nucleoli, and express markers such as CD15 and CD30, distinguishing them from other lymphoid cells. Understanding Reed-Sternberg cells provides crucial insight into Hodgkin lymphoma biology, guides clinical management, and informs the development of targeted therapies. Their presence in lymph nodes and occasional extranodal sites, combined with their interactions with surrounding inflammatory cells, underscores their significance in disease progression and clinical outcomes.